Skip to main content
Funded Studies

Patrik Brundin, MD, PhD

Deputy Chief Scientific Officer at Van Andel Institute

Director, Parkinson’s Disease Center

Professor, Department of Neurodegenerative Science

Jay Van Andel Endowed Chair in Parkinson’s Research

Location: Grand Rapids, MI United States

Patrik Brundin joined the Van Andel Institute in 2012, where he is deputy chief scientific officer and directs the Parkinson’s Disease (PD) Center. He earned a PhD in 1988 and an MD in 1992 from Lund University, Sweden and is highly cited in neuroscience with more than 400 publications on PD and related topics. His research focuses on pathogenic mechanisms of PD and development of therapies that repair damaged brain circuits and slow or stop disease progression. He has 40 years of experience in neural transplantation research, including clinical trials. He is a member of the board of directors for the World Parkinson Coalition and the executive scientific advisory board of The Michael J. Fox Foundation. He also serves as co-editor-in-chief of the Journal of Parkinson’s Disease and chair of the International Linked Clinical Trials scientific committee.


Associated Grants

  • Phase 1b Trial to Assess the Safety and Efficacy of Dopamine Cell Transplants in Parkinson’s Disease Linked to Mutations in Parkin

    2022


  • Targeting the Chemical Modification of DNA to Suppress Neurodegeneration in Parkinson’s Disease

    2021


  • Novel Candidate against Alpha-synuclein for the Treatment of Parkinson’s Disease

    2020


  • Upregulation of Autophagy by Tet3-mediated 5-methylcytosine oxidation – Relevance to Parkinson's Disease

    2016


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.